This brand name is authorized in Japan, United States
The drug REYVOW contains one active pharmaceutical ingredient (API):
1
Lasmiditan
UNII 760I9WM792 - LASMIDITAN
|
Lasmiditan binds with high affinity to the 5-HT1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT1F receptor; however, the precise mechanism is unknown. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
REYVOW Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
N02CC08 | N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: JP | 医薬品医療機器総合機構 | Identifier(s): 1190030F1024, 1190030F2020 |
Country: US | FDA, National Drug Code | Identifier(s): 0002-4312, 0002-4491 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.